MAP2K1 and cancer: Anti-cancer drugs, including ARV-771 [pan-(bromodomain and extra-terminal) BET degrader], IPZ (importazole, importin-β inhibitor), U0126 (selective inhibitor of the MAP kinase kinases MEK1 and MEK2), and LY294002 (PI3-kinase inhibitor) reduced HCT116 cell growth (Figure 5A,B).